Alan Graff
Internal Medicine · Fort Lauderdale, FLNPI 1669471090
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 99.6% of the total across 161 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 23 manufacturers, the largest accounting for just 19.2% — the pattern of someone who eats at a lot of different presentations. Reporting peaked in 2019 at $1,703 and has fallen 83.8% since, to $277 in 2022.
Across 161 payments — averaging $20.35 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Johnson & Johnson$628
- AstraZeneca$548
- Novo Nordisk$503
- Amgen$264
- Lilly USA, LLC$194
- Amarin Pharma, Inc.$192
- plus $948 from 17 others
What the payments were for
- Food & beverage$3,265100%
- Education$120%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Johnson & Johnson | 17 | $628 |
| AstraZeneca | 28 | $548 |
| Novo Nordisk | 30 | $503 |
| Amgen | 10 | $264 |
| Lilly USA, LLC | 13 | $194 |
| Amarin Pharma, Inc. | 11 | $192 |
| Pfizer | 10 | $185 |
| Boehringer Ingelheim | 7 | $133 |
| AbbVie(2 entities) | 7 | $120 |
| Merck | 6 | $110 |
| Bayer | 4 | $82 |
| Sanofi-aventis U.S. LLC | 4 | $65 |
| Novartis | 3 | $51 |
| Astellas Pharma US Inc | 2 | $44 |
| Regeneron Healthcare Solutions, Inc. | 1 | $26 |
| Ultragenyx Pharmaceutical Inc. | 1 | $21 |
| Eisai Inc. | 1 | $19 |
| Kowa Pharmaceuticals America, Inc. | 1 | $19 |
| GSK | 1 | $18 |
| Acerus Pharmaceuticals Corporation | 1 | $18 |
| Corcept Therapeutics | 1 | $14 |
| Aytu Biopharma, Inc. | 1 | $13 |
| Gilead | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$3,277 in reported general payments places this provider in the 85th percentile of 8,530 internal medicine providers in Florida.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 14 | $19,380 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic | $503 | $19,38014 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 8,530 internal medicine providers in Florida.
Other internal medicine in Fort Lauderdale
- Keith RubinFort Lauderdale$2M
- Michael SensionFort Lauderdale$1M
- Sheetal SharmaFort Lauderdale$184K
- Evan WuFort Lauderdale$114K
- Haytham ElgammalMiami$2.2M
- Quang NguyenOcala$434K
- Luis Correa LunaSanford$412K
- Michael OleksykFort Myers$365K
- Andrew KuykendallTampa$322K
- Howard FederoffCoconut Grove$302K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.